Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 240 results for children's cancer

  1. Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation (HTG496)

    Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of livers for transplantation in people of all ages. This involves using a machine to give an oxygenated solution to the donor liver until it is transplanted.

    HealthTech guidance
    Published
    16 January 2019
    View recommendations

    Sections for HTG496

  2. Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

    Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.

    Technology appraisal guidance
    Published
    16 October 2024
    View recommendations

    Sections for TA1011

  3. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    Question Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with...

    Research recommendation
    Published
    9 June 2015

  4. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  5. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  6. clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (MIB278)

    NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .

    Medtech innovation briefing
    Published
    30 November 2021

  7. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

    NICE guideline
    Published
    20 October 2015
    View recommendations

    Sections for NG16

  8. Type 2 diabetes prevention: population and community-level interventions (PH35)

    This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.

    Public health guideline
    Published
    10 May 2011
    View recommendations

    Sections for PH35

  9. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

    Technology appraisal guidance
    Published
    25 August 2004
    View recommendations

    Sections for TA82

  10. AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)

    NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .

    Medtech innovation briefing
    Published
    5 May 2022

  11. AccuVein AV400 for vein visualisation (MIB6)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation

    Medtech innovation briefing
    Published
    23 June 2014

  12. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    4 December 2017

  13. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

    NICE guideline
    Published
    15 January 2019
    View recommendations

    Sections for NG119

  14. How can healthy habits that promote oral health be supported and encouraged in families with children at high risk of poor oral health?

    habits that promote oral health be supported and encouraged in families with children at high risk of poor oral health? Any explanatory...

    Research recommendation
    Published
    9 June 2015

  15. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.